Status:
UNKNOWN
Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.
Lead Sponsor:
Integrated Community Oncology Network
Collaborating Sponsors:
Sanofi
Conditions:
Previously Treated Metastatic Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically ev...
Detailed Description
This is a non-randomized trial for patients with previously treated Non-small cell lung cancer. Each patient will receive 6 cycles of chemotherapy consisting of Oxaliplatin and Navelbine. Oxaliplatin ...
Eligibility Criteria
Inclusion
- Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemo.
- Measurable disease
- Good performance status (ECOG 0,1 or 2)
Exclusion
- Previously treated with Oxaliplatin or Navelbine
- Symptomatic CNS metastases
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00238849
Last Update
October 14 2005
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Integrated Community Oncology Network
Jacksonville, Florida, United States, 32256
2
Integrated Community Oncology Network
Orange Park, Florida, United States, 32073